Importance of interaction between C1 domain and lipids in protein kinase Cα activation: Hydrophobic side chain direction in isobenzofuranone ligands controls enzyme activation level

ChemMedChem

Volumn 2, Issue 7, 2007, Pages 1006-1009

  Hirai, Go ^a   Shimizu, Adashi ^a   Watanabe, Toru ^a,b   Ogoshi, Yosuke ^b   Ohkubo, Megumi ^a,b   Sodeoka, Mikiko ^a  

^a RIKEN   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

Author keywords

Isobenzofuranone; Kinase modulators; Molecular modeling; Protein kinase C ; Structure activity relationships

Indexed keywords

FURAN DERIVATIVE; LIGAND; PROTEIN KINASE C ALPHA;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; ENZYME ACTIVATION; HYDROGEN BOND; METABOLISM; STRUCTURE ACTIVITY RELATION;

ENZYME ACTIVATION; FURANS; HYDROGEN BONDING; LIGANDS; MODELS, MOLECULAR; PROTEIN KINASE C-ALPHA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 49649129954     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.200700080     Document Type: Article

References (29)

1. a) Y. Nishizuka, FASEB J. 1995, 9, 484;
2. b) A. C. Newton, Chem. Rev. 2001, 101, 2353.
3. a) Y. Kishi, R. R. Rando, Acc. Chem. Res. 1998, 31, 163;
4. b) H. Fujiki, Y. Tanaka, R. Miyake, U. Kikkawa, Y. Nishizuka, T. Sugimura, Biochem. Biophys. Res. Commun. 1984, 120, 339;
5. c) R. L. Berkow, A. S. Kraft, Biochem. Biophys. Res. Commun. 1985, 131, 1109;
6. d) J. B. Smith, L. Smith, G. R. Pettit, Biochem. Biophys. Res. Commun. 1985, 132, 939;
7. e) J. P. Arcoleo, I. B. Weinstein, Carcinogenesis 1985, 6, 213.
8. For a discussion of the activation mechanism of PKCα, see: R. V. Stahelin, J. Wang, N. R. Blatner, J. D. Rafter, D. Murray, W. Cho, J. Biol. Chem. 2005, 280, 36452, and references therein.
9. The C1A and C1B domains of PKCα are proposed to have opposite affinities for DAG and phorbol ester; that is, phorbol ester has high affinity for the C1B domain of PKCα. See: a) B. Ananthanarayanan, R. V. Stahelin, M. A. Digman, W. Cho, J. Biol. Chem. 2003, 278, 46886;
10. b) M. Shindo, K. Irie, A. Nakahara, H. Ohigashi, H. Konishi, U. Kikkawa, H. Fukuda, P. A. Wender, Bioorg. Med. Chem. 2001, 9, 2073. Although it is possible that the C1A domain also contributes to phorbol ester binding, in this paper we focus on C1B domain to simplify the discussion. See, also reference [8g].
11. The structure of PKCα have been proposed. See. N. Srinivasan, B. Bax, T. L. Blundell. P. J. Parker, Proteins: Struct. Funct. Genet. 1996, 26, 217.
12. G. Zhang, M. G. Kazanietz, P. M. Blumberg, J. H. Hurley, Cell 1995, 81, 917.
13. a) M. G. Kazanietz, K. W. Krausz, P. M. Blumberg, J. Biol. Chem. 1992, 267, 20878;
14. b) Z. Szallasi, P. M. Blumberg, Cancer Res. 1991, 51, 5355.
15. a) M. Tanaka, K. Irie, Y. Nakagawa, Y. Nakamura, H. Ohigashi, P. A. Wender, Bioorg. Med. Chem. Lett. 2001, 11, 719, and references therein;
16. b) P. A. Wender, V. A. Verma, Org. Lett. 2006, 8, 1893, and references therein;
17. c) H. Nakamura, Y. Kishi, M. A. Pajares, R. R. Rando, Proc. Natl. Acad. Sci. USA 1989, 86, 9672;
18. d) Y. Endo, M. Ohno, M. Hirano, A. Itai, K. Shudo, J. Am. Chem. Soc. 1996, 118, 1841, and references therein;
19. e) Y. Nakagawa, K. Irie, N. Yamanaka, H. Ohigashi, K. Tsuda, Bioorg. Med. Chem. Lett. 2003, 13, 3015, and references therein;
20. f) Z.-L. Wei, S. Sakamuri, P. A. Petukhov, C. George, N. E. Lewin, P. M. Blumberg, A. P. Kozikowski, Org. Lett. 2002, 4, 2169, and references therein;
21. g) Y. Pu, N. A. Perry, D. Yang, N. E. Lewin, N. Kedei, D. C. Braun, S. H. Choi, P. M. Blumberg, S. H. Garfield, J. C. Stone, D. Duan, V. E. Marquez, J. Biol. Chem. 2005, 280. 27 329, and references therein.
22. Phorbol ester derivatives having a hydrophilic side chain have been reported to act as inhibitors; a) M. Sodeoka, M. A. Arai, K. Adachi, K. Uotsu, M. Shibasaki, J. Am. Chem. Soc. 1998, 120, 457;
23. b) R. Wada, Y. Suto, M. Kanai, M. Shibasaki, J. Am. Chem. Soc. 2002, 124, 10658.
24. A few PKC inhibitors are reported to bind C1 domain; a) R. F. Bruns, F. D. Miller, R. L. Merriman, J. J. Howbert, W. F. Heath, E. Kobayashi, I. Takahashi, T. Tamaoki, H. Nakano, Biochem. Biophys. Res. Commun. 1991, 176, 288;
25. b) Y. A. Hannun, C. R. Loomis, A. H. Merrill, Jr., R. M. Bell, J. Biol. Chem. 1986, 261, 12604.
26. a) Y. Baba, Y. Ogoshi, G. Hirai, T. Yanagisawa, K. Nagamatsu, S. Mayumi, Y. Hashimoto, M. Sodeoka, Bioorg. Med. Chem. Lett. 2004, 14, 2963;
27. b) Y. Baba, S. Mayumi, G. Hirai, H. Kawasaki, Y. Ogoshi, T. Yanagisawa, Y. Hashimoto, M. Sodeoka, Bioorg. Med. Chem. Lett. 2004, 14, 2969.
28. R. J. Mills, N. J. Taylor, V. Snieckus, J. Org. Chem. 1989, 54, 4372.
29. Y. Tanaka, R. Miyake, U. Kikkawa, Y. Nishizuka, J. Biochem. 1986, 99, 257.